MedScience Ventures, LLC. (MSV) is a U.S., Europe, and Asia-based fund management company focused on emerging life science and medical technologies.

MSV seeks to partner with innovative, emerging companies to provide consulting services, obtain exclusive license rights in specific markets, and evaluate making equity investments. 

Managing Partners

Stefano Ciampolini is a founder of MedScience Ventures (MSV) and a Member of the General Partner.

Stefano is Honorary Fellow of Imperial College Business School in London and Mentor at Imperial Enterprise Lab’s Venture Mentoring Service, as well as Entrepreneur in Residence and member of the Chair of Entrepreneurship at the Swiss Federal Institute of Technology (ETH Zurich). Stefano is also a jury member of Venture Kick, Switzerland’s largest philanthropic startup accelerator program.

Stefano is a serial healthcare and medical technology entrepreneur in Europe and the US having founded and successfully exited several companies in the dialysis and renal care sector over the last 30 years.

He is also managing partner and founder of Healthcare Capital Partners (London), a private equity and corporate finance advisory boutique specialising in life sciences.

As part of his activities Stefano is a founder, board member and investor in several healthcare and medtech ventures and private equity funds focusing on healthcare and medtech investments in Europe and the US. He was the founder and CEO of Renal Services, a UK dialysis company now part of DaVita, and currently serves as founder and chairman of Pure Life Renal, a US dialysis services company, founder and co-chairman of Renal@Home, a remote patient monitoring company, founder and board member of UV Light Care, a US medical devices company, board member of Yofumo Technologies, a US biomass decontamination company, chairman of Sleepiz, a Swiss respiratory medical devices company spun out of ETH, board member of Pathfinder Medical, a medical devices company spun out of Imperial College, and advisory board member to Liom a Swiss medtech company.

Stefano earned an MBA from Imperial College Business School in London and holds a degree in economics from Kingston University in London.

Stefano Ciampolini
Managing Partner

Sherwyn Hung is a founder of MedScience Ventures (MSV) and a Member of the General Partner. For 27 years, Mr. Hung has worked with U.S. and European multinational pharmaceutical and life science companies. Mr. Hung is currently responsible for PUMC Pharmaceutical’s general management duties. From 1995 to 1999, Mr. Hung served as Chief Operating Officer of National Medical Care/Asia Renal Care, which pioneered the development of organ procurement programs in the Asia Pacific region. During this time, he oversaw the adoption of KDOQI guidelines for CQI throughout Asia Renal Care’s dialysis centers in China, Taiwan, Korea, Singapore, Thailand, and the Philippines. From 1991 to 1994, Mr. Hung served as General Manager of Sandoz Hong Kong and China, and Regional Marketing Director of Sandoz Asia Pacific. During this time, he launched the company’s first organ procurement programs in the Asia Pacific region. Mr. Hung also served as General Manager of SmithKline Beecham Taiwan as Head of Abbott Laboratories' Hospital Division, and as Sales Manager for Eli Lilly Taiwan. Mr. Hung holds an MBA from the Kelley School of Business at Indiana University Bloomington.

Sherwyn Hung
Managing Partner

Christopher Ford is a founder of MedScience Ventures (MSV) and a Member of the General Partner. Since 1999, Mr. Ford has served as Chairman (Ret.) and Co-Founder of American Renal Associates Holdings, Inc. (NYSE: ARA) – one of the largest dialysis providers in the United States and offers an alternative to traditional large dialysis chain ownership. Mr. Ford co-founded ARA in August 1999 with two colleagues from Fresenius Medical Care, the world's largest dialysis company. As of 2018, ARA owns and operates over 240 outpatient dialysis clinics in 27 states and the District of Columbia (with 28 new clinics in the pipeline), treats over 16,000 patients, and has over 4,000 employees, including more than 400 nephrologists. Mr. Ford also formerly served as President of Fresenius's International Services Division. During his tenure as President of Fresenius’s International Services Division, he grew the division from a small presence in Spain and Portugal to a worldwide organization, providing care for 10,000 chronic dialysis patients in fourteen countries. Prior to serving as President of Fresenius’s International Services Division, Mr. Ford was responsible for all of Fresenius’s U.S. operations and served as Senior Vice President of Operations for the U.S. Dialysis Services Division. He has worked in the dialysis services industry since 1971, and during his career (which spans over forty years) he has contributed to the build-out of the U.S. dialysis market from its infancy in the 1970's to a $19 billion healthcare business today. Mr. Ford received his BS degree in Business Administration from Northeastern University in Boston, MA.

Christopher Ford
Managing Partner

Nick Wu is a Member of the MedScience Ventures (MSV) General Partner and a healthcare and medical device professional who has more than 30 years of experience serving as a member of senior management for leading multi-national medical device and healthcare companies. Mr. Wu has extensive experience in international medical device sales and marketing management and has a robust international medical device professional network, including networks in the Greater China and Asia Pacific regions. In particular, Mr. Wu has experience in medical device sales and marketing and healthcare management in the hemodialysis, surgical, blood banking, dental, cardiology, and radiology fields. He also has experience in nursing home management and medical device manufacturing. Mr. Wu began his professional career with B. Braun in Taiwan, where he dealt in surgical instruments, sutures, orthopedic implants and medical disposables, and later joined Terumo, a large medical device company, as Taiwan Country Manager. In 2000, he joined Gambro, a medical technology company, as General Manager of Gambro Taiwan and President and Chief Executive Officer of Gambro Asia-Pacific. Mr. Wu has served as President of Quality System Control Inc., a company engaged in the business of medical device and automotive parts manufacturing, since 2015. Mr. Wu earned his master’s degree in EMBA from the National Taiwan University of Science and Technology and earned his second master’s degree in Biomedical Engineering from Taipei Medical University.

Nick Wu
Managing Partner

Bret Siarkowski is a founder of MedScience Ventures (MSV) and a Member of the General Partner. Mr. Siarkowski is a seasoned entrepreneur with over 20 years of experience initiating and leading technology companies in the design and application of innovative market-demanded solutions, as well as creating new markets. His extensive experience spans the mobile, gaming, healthcare, software, semiconductor and electronics industries. Mr. Siarkowski is a Limited Partner at Kodiak Venture Partners, an angel investor, and serves on the board of advisors for several technology companies. Mr. Siarkowski holds a BSEE from Northeastern University in Boston, MA and an MSEE from the University of Southern California in Los Angeles, CA. He also is the holder of several patents that cover both software and hardware industries.

Bret Siarkowski
Managing Partner

Associates & Staff

Ashley Ford
Managing Director

Yang Gao
Business Development Director

Yi Liu
Business Development Manager

Casey Ford
Managing Director

Jason Hung
Business Development Manager

 

Chiwen Hung
Managing Director

Jeffrey Hung
Business Development Manager

 

Gus Adapon
Director of Investor Relations

David Stanton
Operations Manager

Andy Chen
Business Development Manager